BSCCG
MRNA icon

Blue Sky Capital Consultants Group’s Moderna MRNA Stock Holding History

Blue Sky Capital Consultants Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
20,588
+143
+0.7% +$6.67K 0.5% 38
2025
Q4 		$603K Buy
20,445
+1,359
+7% +$36.9K 0.26% 44
2025
Q3 		$493K Buy
19,086
+2,732
+17% +$76.2K 0.21% 46
2025
Q2 		$451K Buy
16,354
+1,235
+8% +$32.5K 0.23% 43
2025
Q1 		$429K Buy
15,119
+556
+4% +$19.7K 0.28% 41
2024
Q4 		$606K Buy
+14,563
New +$696K 0.36% 38

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Blue Sky Capital Consultants Group's MRNA Position: Q1 2026 in Review

Blue Sky Capital Consultants Group increased its Moderna (MRNA) stake by 0.7% in Q1 2026, buying an estimated $6.67K and bringing the position to 20,588 shares worth $1.05M. The position accounts for 0.5% of the portfolio, ranked #38.

Blue Sky Capital Consultants Group first reported a position in MRNA in Q4 2024 and has held it in 6 quarters since. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Blue Sky Capital Consultants Group held 20,588 shares of Moderna worth $1.05M as of Q1 2026.
  • Blue Sky Capital Consultants Group bought 143 Moderna shares in Q1 2026, an estimated $6.67K.
  • Moderna made up 0.5% of Blue Sky Capital Consultants Group's portfolio in Q1 2026, its #38 holding.
  • Blue Sky Capital Consultants Group first reported a position in Moderna in Q4 2024 and has held it in 6 quarters since.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Blue Sky Capital Consultants Group's 13F filing for Q1 2026, filed 28 Apr 2026.